Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Immunotherapy of cancer 2

1428 - Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations


22 Oct 2018


Poster Discussion session - Immunotherapy of cancer 2


Tumour Immunology;  Targeted Therapy;  Immunotherapy

Tumour Site


Jason Luke


Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288


J.J. Luke1, R. Edwards2, C. Hedvat2, D. Pandya2, S. Ely2, R. Meier3, D. McDonald2, C.T. Harbison3, V. Baxi2, G. Lee2, P. Szabo2, T. Garcia4, R. Bao4, T.P. Reilly3, E. Jaffee5, F.S. Hodi6

Author affiliations

  • 1 Department Of Medicine, The University of Chicago Medical Center, 60637-1470 - Chicago/US
  • 2 Immuno-oncology, Bristol-Myers Squibb, Princeton/US
  • 3 Immuno-oncology, Bristol-Myers Squibb, 08540 - Princeton/US
  • 4 Center For Research Informatics, The University of Chicago Medical Center, 60637-1470 - Chicago/US
  • 5 Department Of Medical Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy, 21287 - Baltimore/US
  • 6 Department Of Medical Oncology, Dana-Farber Cancer Institute, Boston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1428


Enhanced understanding of the TME can enable precision medicine–driven patient (pt) selection to identify pts more likely to benefit from IO therapy (Hellman MD, et al. N Engl J Med 2018; Overman MJ, et al. Lancet Oncol 2017).


The Cancer Genome Atlas (TCGA) RNA data (melanoma, NSCLC, RCC, UC, SCCHN, GEJ) were normalized and grouped as inflamed (INF), intermediate (INT), or non-INF. Binary associations of PD1 with IO targets (LAG3, IDO1, FOXP3, GITR, CSF1R, KIRDL1, CTLA4) were studied. Unsupervised clustering and pt-level gene expression profiling (GEP) were performed. A separate set of tumors was analyzed by IHC (N = 228; LAG-3, IDO-1, FOXP3, GITR, CSF-1R, NKp46, PD-L1, MHCI, MHCII, CD8, CD68, CD163) and matched mRNA analysis (EdgeSeq; n = 128). IHC results were integrated into an algorithm for IO combination selection.


TCGA analysis showed associations of IO targets and PD1 (mean Pearson r ± SEM = 0.62 ± 0.03; P < 0.0001). Unsupervised clustering revealed discrete groups of INT tumors with high T-cell anergy, regulatory T cell, or myeloid signatures. Pt-level GEP showed INT/low-PDL1 tumors as most likely to have outlier IO targets suggestive of functional relevance. IHC showed clustering of IO targets by INF level, with outliers in INT/low-INF tumors and variability by tumor type. Observations were verified by selected IHC markers showing significant association of expression level and INF score: IDO-1, LAG-3 (non-INF vs INT P = 0.17–1.9E-04; INT vs INF P = 0.001–0.03); FOXP3, GITR, NKp46 (INT vs INF P = 0.001–0.049). CSF-1R did not show significant associations. These data aided in the design of the ADaptiVe biomarker trial that InformS Evolution of therapy (ADVISE; NCT03335540), where prospective treatment selection (nivolumab + second IO agent) is driven by analysis of pretreatment biopsies. Initial clinical implementation will also be presented.


Translational data reveal potentially actionable biomarkers, which are being assessed in the ongoing ADVISE trial as an initial clinical foray into personalized IO therapy.

Clinical trial identification

Legal entity responsible for the study

Bristol-Myers Squibb.


Bristol-Myers Squibb.

Editorial Acknowledgement

Writing and editorial assistance was provided by Larra Yuelling, PhD of Chrysalis Medical Communications, Inc., funded by Bristol-Myers Squibb.


J.J. Luke: Consultancy: 7 Hills, Actym, Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, Compugen, EMD Serono, Gilead, Janssen, Merck, NewLink, Nimbus, Novartis, Palleon, RefleXion, Syndax, Tempest, TTC Oncology, WntRx; Research support: AbbVie, Array, Boston Biomedical, Bristol-Myers Squibb, Celldex, CheckMate, Corvus, Delcath, Five Prime, Genentech, Immunocore, Incyte, MedImmune, Macrogenics, Novartis, Pharmacyclics, Palleon, Merck, Tesaro, Xencor; Travel: Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Janssen, Merck, NewLink, Novartis, RefleXion. R. Edwards, C. Hedvat, D. Pandya, R. Meier, C.T. Harbison, P. Szabo: Employment: Bristol-Myers Squibb; Stock: Bristol-Myers Squibb. S. Ely: Employment: Bristol-Myers Squibb; Stock: Bristol-Myers Squibb; Patents/Royalties/Property: Cornell University. D. McDonald, G. Lee: Employment: Bristol-Myers Squibb; Stock: Bristol-Myers Squibb; Travel and accommodations: Bristol-Myers Squibb. V. Baxi, T.P. Reilly: Employment: Bristol-Myers Squibb; Stock: Bristol-Myers Squibb. E. Jaffee: Consulting/Advisory: Aduro Biotech, MedImmune, Incyte, Genocea; Research funding: Bristol-Myers Squibb, Aduro Biotech, Amgen; Patents/Royalties: Potential royalties from Aduro for GVAX. F.S. Hodi: Consulting/Advisory role: Novartis, Amgen, EMD Serono, Celldex, Merck, Bristol-Myers Squibb; Research funding: Bristol-Myers Squibb; Patents, royalties, other intellectual property: Dana-Farber Cancer Institute. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.